Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS).
Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, Lambert T, Kaczmarek R, Carbonero D, Makris M; European HAemophilia Safety Surveillance (EUHASS) participants. Fischer K, et al. Among authors: lambert t. Res Pract Thromb Haemost. 2024 May 27;8(4):102461. doi: 10.1016/j.rpth.2024.102461. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 39026659 Free PMC article.
Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada.
Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettle A, Samji N, Rivard GÉ, Carcao M, Iorio A, Makris M; EUHASS and CHESS participants. Fischer K, et al. Among authors: lambert t. Res Pract Thromb Haemost. 2023 Nov 20;7(8):102265. doi: 10.1016/j.rpth.2023.102265. eCollection 2023 Nov. Res Pract Thromb Haemost. 2023. PMID: 38193044 Free PMC article.
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K; European Haemophilia Therapy Standardisation Board. Astermark J, et al. Haemophilia. 2010 Sep 1;16(5):747-66. doi: 10.1111/j.1365-2516.2010.02231.x. Epub 2010 Apr 14. Haemophilia. 2010. PMID: 20398077 Review.
Continuous infusion in haemophilia: current practice in Europe.
Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K; European Haemophilia Treatment Standardisation Board. Batorova A, et al. Haemophilia. 2012 Sep;18(5):753-9. doi: 10.1111/j.1365-2516.2012.02810.x. Epub 2012 Apr 25. Haemophilia. 2012. PMID: 22530687
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group. Collins PW, et al. J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20. J Thromb Haemost. 2009. PMID: 19143924 Free article. Clinical Trial.
764 results